Genix Pharmaceuticals Corporation
GENPF · OTC
4/30/2025 | 1/31/2025 | 10/31/2024 | 7/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | 0.05 | -0.02 | 1.49 |
| FCF Yield | -0.44% | -1.83% | -1.22% | -1.40% |
| EV / EBITDA | -461.21 | -64.57 | 21.64 | -81.39 |
| Quality | ||||
| ROIC | 7.36% | 13.56% | 26.65% | 7.63% |
| Gross Margin | 0.00% | 0.00% | -1,476.47% | 64.16% |
| Cash Conversion Ratio | 0.14 | 0.27 | 0.59 | -0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -82.34% | -52.03% | 36.01% | 159,311.90% |
| Free Cash Flow Growth | 77.43% | -56.38% | 12.15% | 21.48% |
| Safety | ||||
| Net Debt / EBITDA | -104.77 | -13.45 | 4.24 | -14.83 |
| Interest Coverage | -0.65 | -1.31 | -2.76 | -1.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -4,900.97 | -25,679.58 |